Sara G. Danielli

Zurich, ZH 8032, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Author Correction: Multidimensional profiling of heterogeneity in supratentorial ependymomas.

Author Correction: Multidimensional profiling of heterogeneity in supratentorial ependymomas.

Journal: Nature

Published: May 06, 2026

Optimized L1CAM-CAR T cells enhance activity against moderate-antigen-density rhabdomyosarcoma models.

Optimized L1CAM-CAR T cells enhance activity against moderate-antigen-density rhabdomyosarcoma models.

Journal: Cancer letters

Published: January 05, 2026

Optimized L1CAM-CAR T cells enhance activity against moderate-antigen-density rhabdomyosarcoma models.

Optimized L1CAM-CAR T cells enhance activity against moderate-antigen-density rhabdomyosarcoma models.

Journal: Cancer letters

Published: January 05, 2026

MYOD1 mutation drives cancer stem cell pathways and therapy-resistance in spindle cell/sclerosing rhabdomyosarcoma.

MYOD1 mutation drives cancer stem cell pathways and therapy-resistance in spindle cell/sclerosing rhabdomyosarcoma.

Journal: Nature communications

Published: March 27, 2025

Single-cell multidimensional profiling of tumor cell heterogeneity in supratentorial ependymomas.

Single-cell multidimensional profiling of tumor cell heterogeneity in supratentorial ependymomas.

Journal: bioRxiv : the preprint server for biology

Published: August 09, 2024

Multidimensional profiling of heterogeneity in supratentorial ependymomas.

Multidimensional profiling of heterogeneity in supratentorial ependymomas.

Journal: Nature

Published: August 07, 2024

Single cell transcriptomic profiling identifies tumor-acquired and therapy-resistant cell states in pediatric rhabdomyosarcoma.

Single cell transcriptomic profiling identifies tumor-acquired and therapy-resistant cell states in pediatric rhabdomyosarcoma.

Journal: Nature communications

Published: October 26, 2023

Evaluation of the Role of AXL in Fusion-positive Pediatric Rhabdomyosarcoma Identifies the Small-molecule Inhibitor Bemcentinib (BGB324) as Potent Chemosensitizer.

Evaluation of the Role of AXL in Fusion-positive Pediatric Rhabdomyosarcoma Identifies the Small-molecule Inhibitor Bemcentinib (BGB324) as Potent Chemosensitizer.

Journal: Molecular cancer therapeutics

Published: May 23, 2023

Genomic and Epigenetic Changes Drive Aberrant Skeletal Muscle Differentiation in Rhabdomyosarcoma.

Genomic and Epigenetic Changes Drive Aberrant Skeletal Muscle Differentiation in Rhabdomyosarcoma.

Journal: Cancers

Published: March 19, 2023

Single-cell profiling of alveolar rhabdomyosarcoma reveals RAS pathway inhibitors as cell-fate hijackers with therapeutic relevance.

Single-cell profiling of alveolar rhabdomyosarcoma reveals RAS pathway inhibitors as cell-fate hijackers with therapeutic relevance.

Journal: Science advances

Published: February 08, 2023

PAX3-FOXO1 uses its activation domain to recruit CBP/P300 and shape RNA Pol2 cluster distribution.

PAX3-FOXO1 uses its activation domain to recruit CBP/P300 and shape RNA Pol2 cluster distribution.

Journal: Nature communications

Published: November 29, 2022

Molecular Characterization of Circulating Tumor DNA in Pediatric Rhabdomyosarcoma: A Feasibility Study.

Molecular Characterization of Circulating Tumor DNA in Pediatric Rhabdomyosarcoma: A Feasibility Study.

Journal: JCO precision oncology

Published: October 20, 2022

Showing 1-12 of 13

Last Updated: 09/26/2026